Phase 3 trial

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the first ... Read more

January 3, 2019

Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins

News

Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. The ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

July 20, 2018

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

News

Adding Imbruvica (ibrutinib) to a standard chemotherapy regimen does not improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), a Phase 3 trial ... Read more

June 6, 2018

Phase 3 Trial to Test Yescarta as Second-line Therapy for DLBCL Patients

News

Kite Pharma has opened a new Phase 3 clinical trial to investigate the effectiveness of Yescarta (axicabtagene ciloleucel) as a second-line therapy for patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

May 21, 2018

Arranon Add-on Improves Long-term Outcomes in Young Patients with T-cell Cancers, Trial Shows

News

A combination of Arranon (nelarabine) and standard chemotherapy led to the highest survival rates seen to date in children and young adults with T-cell acute lymphoblastic leukemia (T-ALL), a Phase ... Read more

September 20, 2017September 20, 2017

Biosimilar GP2013 Is Equivalent to Rituxan as Lymphoma Therapy, Phase 3 Trial Shows

News

Lymphoma patients’ response to Sandoz’s biosimilar therapy GP2013 was similar to their response to the treatment from which it is derived, Genentech’s Rituxan (rituximab), a Phase 3 clinical trial indicates. Sandoz presented ... Read more